Second Pipeline Shift for Survival

TScan Therapeutics (TCRX) has decided to reduce its workforce by approximately 75%, eliminating a significant portion of its internal manufacturing and research functions. This is an additional restructuring following a 30% reduction in 2025, with associated severance costs estimated at USD 4.1 million. The company aims to save a cumulative USD 55 million by the end of 2027, extending its cash runway to the fourth quarter of 2027. The company's Nasdaq stock has traded below USD 1 for 30 consecutive trading days, requiring it to regain compliance with listing requirements by February 23, 2027, which is increasing capital-raising pressure.

TSC-101 Clinical Trial Halted Due to Capital Shortfall

TSC-101, which has not yet received a non-proprietary or brand name, is a donor-derived T-cell receptor-engineered T-cell therapy (TCR-T) targeting the HA-2 antigen presented by HLA-A*02:01. It was designed to suppress residual disease and recurrence in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) following allogeneic hematopoietic stem cell transplantation. All 13 patients tracked in Phase 1 ALLOHA cohort C showed complete donor chimerism, but two patients who relapsed and received additional TSC-101 or targeted therapy were also included, making interpretation of monotherapy effects cautious. Due to capital constraints, the company has halted the new registration for Phase 3 ALLOHA-2 and is now only treating and tracking the 7 patients already in the treatment group, while seeking partners.

Restarting with PRAME and MAGE-A4 In Vivo TCR-T

The new core assets are single-agent in vivo engineered TCR-T candidates targeting the cancer-testis antigens PRAME and MAGE-A4, currently in IND-enabling stages. The strategy uses a lentiviral vector to directly modify T-cells within the patient, reducing the burden of individual cell collection, external manufacturing, and lymphodepletion. Preclinical data are expected in Q1 2027, the first IND submission in Q3 2027, and the start of Phase 1 in Q4 2027. PRAME is expressed in over 90% of melanomas, while MAGE-A4 is observed in non-small cell lung cancer, ovarian cancer, and head and neck cancers, offering a broad target range. However, as these are preclinical candidates, subsequent funding and proof of in vivo gene delivery safety and efficiency are prerequisites for value creation.

Implications of Approved Competitors and a Large Market

In the MAGE-A4 space, Adaptimmune's Tecelra (afamitresgene autoleucel) has been granted accelerated FDA approval for HLA-A*02 and MAGE-A4 positive progressive synovial sarcoma in patients with prior chemotherapy experience, effective August 2, 2024. This is the first FDA-approved TCR gene therapy, with no advisory committee (AdComm) convened, and it requires patient-specific ex vivo manufacturing and lymphodepletion, setting a direct technical benchmark for TScan's in vivo approach. Standard treatments for multiple tumor types include Merck & Co. (MRK)'s Keytruda (pembrolizumab, PD-1 target) based immunotherapy, as well as surgery, radiation, and chemotherapy. According to IQVIA, global solid tumor drug sales are expected to reach approximately USD 194 billion in 2025, but TScan must demonstrate safety, response durability, and manufacturing advantages in early clinical trials to access this market.

Financial Impact of Terminated Amgen Agreement

Amgen (AMGN) terminated its Crohn's disease target discovery agreement with TScan in August 2026, which had started in 2023. The agreement included an upfront payment of USD 30 million, development and commercialization milestones exceeding USD 500 million, and single-digit royalties based on net sales. However, the termination has erased the unrealized economic value. This restructuring, occurring immediately after the loss of this funding option, shifts the focus from hematologic and autoimmune assets to partner-seeking for these two solid tumor candidates. While cost-cutting extends the short-term survival period, the reduction in clinical and manufacturing personnel increases the risk of executing the two INDs and Phase 1 trials as planned.